Biovica strengthens with new R&D Director

Published on: 18 Nov 2019

Otti Bengtsson Gref has a long experience of leading positions in the R&D field in the commercial diagnostic industry. Otti most recently comes from the role as R&D Director at Cavidi. She has held various managerial positions in R&D at IDD, Thermo Fisher Scientific from 2010 to 2018, and before that, from 2003 to 2010, she was a specialist, product manager and finally head of Product Management at Phadia. Otti Bengtsson Gref is Med. Lic in Immunology and also holds an Executive MBA. She will take up her position as R&D Director on January 7, 2020.

“I look forward to start working for Biovica and DiviTum. I am impressed by how far the company has come in developing the product, collaborations with leading oncologists and the results that have come from these collaborations. I look forward to contributing to the approval of DiviTum so that it can be used to contribute to better treatment for cancer patients in the world,” says Otti Bengtsson Gref.

“We are very pleased to have recruited Otti as new head of R&D. Her expertise and her experience in developing diagnostic products that have gone through regulatory approval and commercialization make her ideal for Biovica. We look forward to having Otti in the team as we continue to develop Biovica's market expansion and take DiviTum to the market for the benefit of patients and society," says Anders Rylander, CEO of Biovica.

Biovica – Best Treatment from Day One.
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica’s assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medicines Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser,, +46 8 528 00 399. For more information please visit: